Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Ginkgo Biloba Extract EGB761 Ameliorates the Extracellular Matrix Accumulation and Mesenchymal Transformation of Renal Tubules in Diabetic Kidney Disease by Inhibiting Endoplasmic Reticulum Stress.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
    • Publication Information:
      Publication: 2024- : [Hoboken, NJ] : Wiley
      Original Publication: New York, NY : Hindawi Pub. Co.
    • Subject Terms:
    • Abstract:
      Competing Interests: The author(s) declare(s) that they have no conflicts of interest.
      The study is aimed at investigating the effects of Ginkgo biloba extract EGB761 on renal tubular damage and endoplasmic reticulum stress (ERS) in diabetic kidney disease (DKD). A total of 50 C57BL/6 N mice were randomly divided into the normal group, DKD group, DKD+EGB761 group (36 mg/kg), and DKD+4-phenylbutyrate (4-PBA) group (1 g/kg). The DKD model was replicated by high-fat diet combined with intraperitoneal injection of streptozotocin (STZ). Renal tubular epithelial cells (HK-2) were divided into the control group, high-glucose group (30 mmol/L), EGB761 group (40 mg/L, 20 mg/L, 10 mg/L), TM group, and TM+4-PBA group. After 8 weeks of administration, expressions of serum creatinine (Scr), blood urea nitrogen (BUN), 24 h urinary protein (24 h Pro), fasting blood glucose (FBG), β2 -microglobulin ( β2 -MG), and retinol binding protein 4 (RBP4) of mice were tested. The pathological changes of renal tissue were observed. The expressions of extracellular matrix (ECM) accumulation and epithelial-mesenchymal transition (EMT) markers α -smooth muscle actin ( α -SMA), E-cadherin, fibronectin, and collagen IV, as well as the ERS markers GRP78 and ATF6, were tested by Western blot, qPCR, immunohistochemistry, or immunofluorescence. EGB761 could decrease the Scr, BUN, 24 h Pro, and FBG levels in the DKD group, alleviate renal pathological injury, decrease urine β2 -MG, RBP4 levels, and decrease the expression of α -SMA, collagen IV, fibronectin, and GRP78, as well as ATF6, while increase the expression of E-cadherin. These findings demonstrate that EGB761 can improve renal function, reduce tubular injury, and ameliorate ECM accumulation and EMT in DKD kidney tubules, and the mechanism may be related to the inhibition of ERS.
      (Copyright © 2021 Jiarui Han et al.)
    • References:
      J Histochem Cytochem. 2019 Sep;67(9):643-661. (PMID: 31116062)
      J Diabetes Res. 2017;2017:8637138. (PMID: 28316995)
      Acta Pharmacol Sin. 2007 Jun;28(6):818-28. (PMID: 17506941)
      Nat Rev Nephrol. 2015 May;11(5):264-76. (PMID: 25643664)
      Am J Kidney Dis. 2018 Jun;71(6):884-895. (PMID: 29398179)
      Nat Med. 2015 Sep;21(9):998-1009. (PMID: 26236991)
      Kidney Int. 2010 Oct;78(8):737-44. (PMID: 20703212)
      Annu Rev Physiol. 2018 Feb 10;80:309-326. (PMID: 29068765)
      Diabetes. 2018 Oct;67(10):2096-2106. (PMID: 30065034)
      Medicine (Baltimore). 2020 Aug 28;99(35):e21959. (PMID: 32871945)
      Chem Biol Interact. 2015 Oct 5;240:292-303. (PMID: 26341651)
      Phytomedicine. 2015 Nov 15;22(12):1071-8. (PMID: 26547529)
      Kidney Int. 2018 Mar;93(3):568-579. (PMID: 29361307)
      Med Mol Morphol. 2017 Mar;50(1):1-8. (PMID: 27438710)
      J Nephrol. 2017 Dec;30(6):701-717. (PMID: 28840540)
      Pharmacol Res. 2019 Aug;146:104314. (PMID: 31229564)
      Nat Rev Nephrol. 2016 Feb;12(2):73-81. (PMID: 26553517)
      Oncotarget. 2016 Apr 19;7(16):22116-27. (PMID: 26959118)
      Exp Mol Pathol. 2015 Apr;98(2):286-94. (PMID: 25595916)
      Nephron Exp Nephrol. 2014;126(3):127-40. (PMID: 24863135)
      Kidney Blood Press Res. 2016;41(4):434-49. (PMID: 27467277)
      Curr Vasc Pharmacol. 2017;15(6):532-548. (PMID: 28707602)
      Eur J Pharmacol. 2016 Nov 15;791:8-24. (PMID: 27568833)
      Chin J Integr Med. 2005 Sep;11(3):226-8. (PMID: 16181540)
      Curr Diab Rep. 2017 Mar;17(3):17. (PMID: 28271468)
      Pediatr Nephrol. 2016 May;31(5):693-706. (PMID: 26208584)
      Evid Based Complement Alternat Med. 2013;2013:689142. (PMID: 23533513)
      Invest Ophthalmol Vis Sci. 2012 Oct 01;53(11):7159-66. (PMID: 22956602)
    • Accession Number:
      0 (Endoplasmic Reticulum Chaperone BiP)
      0 (HSPA5 protein, human)
      0 (Hspa5 protein, mouse)
      0 (Plant Extracts)
      0 (Rbp4 protein, mouse)
      0 (Retinol-Binding Proteins, Plasma)
      0 (beta 2-Microglobulin)
      19FUJ2C58T (Ginkgo biloba extract)
    • Publication Date:
      Date Created: 20210416 Date Completed: 20210525 Latest Revision: 20240226
    • Publication Date:
      20250114
    • Accession Number:
      PMC8009711
    • Accession Number:
      10.1155/2021/6657206
    • Accession Number:
      33860049